JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266696

Human LYPLA2 (APT-2) knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

LYPLA2 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 2.

View Alternative Names

APT-2, Acyl protein thioesterase, Acyl-protein thioesterase 2, DJ886K2.4, EC 3.1.2.-, LPL-I, LPL-II, LYPA2_HUMAN, LYPLA 2, LysoPLA II, Lysophospholipase II, OTTHUMP00000002999, OTTHUMP00000044831

1 Images
Sanger Sequencing - Human LYPLA2 (APT-2) knockout HEK-293T cell line (AB266696)
  • Sanger seq

Unknown

Sanger Sequencing - Human LYPLA2 (APT-2) knockout HEK-293T cell line (AB266696)

Homozygous : 7 bp deletion in exon2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 2

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266696-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266696 Human LYPLA2 (APT-2) knockout HEK-293T cell line", "number":"AB266696-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266696-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266696 Human LYPLA2 (APT-2) knockout HEK-293T cell line", "number":"AB266696-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
LYPLA2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

APT-2 also known as lysophospholipase A2 (lypla2) is an enzyme involved in lipid metabolism. APT-2 has a molecular mass of approximately 25 kDa and is expressed in various tissues including the brain heart and muscle. As an important member of the lipid acyl hydrolase family it removes fatty acids from lysophospholipids. Researchers often use the names anti-APT and anti-ApT in antibody studies targeting this enzyme. APT-2 identification in these tissues highlights its importance in lipid processing and suggests its broader functional implications.
Biological function summary

APT-2 plays a critical role in maintaining phospholipid homeostasis contributing to membrane fluidity and signal transduction. It is involved in hydrolyzing lysophospholipids into lysoglycerophospholipids and free fatty acids. Not part of a complex APT-2 acts as an individual enzyme handling specific substrates in this context. Its activity regulates levels of lipid signaling molecules influencing cellular responses to environmental cues. APT-2 also contributes to energy storage via metabolism of lipid substrates linking its enzymatic activity to broader metabolic pathways.

Pathways

APT-2 holds significance in both metabolic and signaling pathways specifically the glycerophospholipid metabolism and lysophospholipid signaling pathways. It catalyzes reactions key to these pathways and intersects with proteins like phospholipase A2 and PLA2G6. Glycerophospholipid metabolism sees APT-2 breaking down molecules to sustain membrane integrity and cellular communication processes. In lysophospholipid signaling its activity regulates bioactive lipid levels which impact a variety of cellular signaling events showing a well-integrated role in cellular physiology.

The dysfunction of APT-2 links to neurodegenerative diseases and cardiovascular disorders. Altered APT-2 activity is associated with Alzheimer's disease due to disrupted lipid homeostasis and membrane composition. The enzyme's interaction with proteins like phospholipase A2 highlights its involvement in these neurodegenerative processes. Furthermore cardiovascular health implications arise from its role in lysophospholipid metabolism and associated inflammatory responses. Aberrations in APT-2 function can modulate pathways that exacerbate atherosclerosis further connecting its activity to disease states.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com